CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Cancer and Genetics

ONCOLOGY. Vol. 25 No. 6
RESEARCH REPORT 

Link Found Between Inflammation and Cancer

April 27, 2011

A group of researchers at the Ohio State University Comprehensive Cancer Center (OSUCCC) has discovered that a certain type of RNA, microRNA-155, may provide the link between inflammation and cancer. The article describing the study was published online ahead of print in the Proceedings of the National Academy of Science in March (doi: 10.1073/pnas.1101795108).


Carlo M. Croce, MD
Ohio State University
Comprehensive Cancer Center

Many studies have linked chronic inflammation with cancer (ie, inflammatory bowel disease and colorectal cancer), and some estimate that as many as 25% of cancer cases are caused by chronic infection. This study, led by Carlo Croce, showed that inflammation stimulates a rise in levels of micro-RNA-155 (miR-155), and that this, in turn, causes a drop in levels of the proteins involved in DNA repair and results in a higher rate of the spontaneous gene mutations that can lead to cancer.

First author and post-doctoral researcher Esmerina Tili said, “Our study shows that miR-155 is upregulated by inflammatory stimuli and that overexpression of miR-155 increases the spontaneous mutation rate, which can contribute to tumorigenesis. People have suspected for some time that inflammation plays an important role in cancer, and our study presents a molecular mechanism that explains how it happens.”

MicroRNAs are involved in many important cell processes and act by suppressing the amounts of certain proteins; each type of microRNA can affect many different proteins. MiR-155 is known to influence blood-cell maturation, immune responses, and autoimmune disorders, and high levels of the molecule have been directly linked to the development of leukemias as well as breast, lung, and gastric cancers.

In the study, Tili and her colleagues examined the effects of inflammation-promoting substances such as tumor necrosis factor or lipopolysaccharide on miR-155 expression and on the frequency of spontaneous mutations in several breast-cancer cell lines. When the researchers exposed breast-cancer cells to the two inflammatory factors, the levels of miR-155 rose to abnormally high levels, and the mutation rate increased two- to three-fold. To understand why, the investigators focused on WEE1, a kinase that stops the process of cell division to allow damaged DNA to be repaired.

The investigators learned that miR-155 also targets WEE1 and showed that high levels of miR-155 lead to low levels of WEE1. They reasoned that low levels of WEE1 allowed cell division to continue even when DNA damage is present, and that this leads to an increased number of mutations.

“Our study suggests that miR-155, which is associated with inflammation, increases the mutation rate and might be a key player in inflammation-induced cancers generally,” said principal investigator Dr. Carlo M. Croce, professor and chair of molecular virology, immunology and medical genetics, and director of the Human Cancer Genetics program at the OSUCCC – James Cancer Hospital. “This could make miR-155 an important therapeutic target.”

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





CancerNetwork on Facebook


 
RELATED CONTENT

New Therapeutic Target, MDM4, Found in Cutaneous Melanoma
July 24, 2012
Study Finds Different Treatment Responses Between BRCA2- and BRCA1-Mutated Ovarian Cancers
ONCOLOGY,  October 11, 2011
Screening Identifies Mechanisms of Drug Resistance to PI3K Inhibitors
ONCOLOGY,  September 27, 2011
Novel DNA-Silencing Function of BRCA1 Discovered
ONCOLOGY,  September 7, 2011
Role for PTEN in DNA Damage Removal and Prevention of Non-Melanoma Skin Cancer
July 28, 2011
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Colorectal Cancer Treatments and Therapy Innovations
  • A 52-Year-Old Man Presents With an Erythematous Lesion
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Preventing Exposure to Hazardous Drugs
  • Conflicts of Interest in Medicine: What About Ties to Payers?
  • Planning Treatment for Women With Recurrent Epithelial Ovarian Cancer
  • Rising PSA Level in a 46-Year-Old Man
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
Click here to subscribe to our newsletter


 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Cancer And Genetics
Evidence on Cancer And Genetics
Guidelines on Cancer And Genetics
Patient Education on Cancer And Genetics
Clinical Trials on Cancer And Genetics
Practical Articles on Cancer And Genetics
Research and Reviews on Cancer And Genetics
All "Cancer And Genetics" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy